- Aeterna Zentaris is a micro-cap biopharmaceutical company with a strong pipeline of oncology and endocrinology candidates.
- NDA for Macrilen, a diagnostic for adult growth hormone deficiency, is currently awaiting decision, with a PDUFA date of November 5, 2014. The annual market opportunity is approx $200m.
- The co-promotion agreement for EstroGel is expected to bring in revenue in the last quarter of the year. The agreement also covers promotional activities for Macrilen.
- Sound management, a strong pipeline, and important catalysts make the company a good long-term investment. And the current low of the stock price is a good entry point.